Quantcast
Last updated on April 23, 2014 at 13:51 EDT

Latest B-cell chronic lymphocytic leukemia Stories

2013-07-29 13:04:46

Study demonstrates technique to create better anti-cancer agents, arthritis drugs, and more Many drugs such as agents for cancer or autoimmune diseases have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now a new study has demonstrated a technique for developing more targeted drugs, by using molecular "robots" to hone in on more specific populations of cells. "This is a proof of concept study using human cells," said Sergei Rudchenko,...

2013-07-25 23:03:21

The Feinstein Institute for Medical Research announced today it will receive a $250,000 grant aimed at gaining a better understanding of chronic lymphocytic leukemia (CLL) and other blood cancers. MANHASSET, NY (PRWEB) July 25, 2013 The Feinstein Institute for Medical Research announced today it will receive a $250,000 grant aimed at gaining a better understanding of chronic lymphocytic leukemia (CLL) and other blood cancers. The two-year grant from the Lymphoma Research Foundation...

2013-07-10 08:26:41

If approved, ibrutinib will address a high unmet need in relapsed/refractory chronic lymphocytic leukemia and relapsed/refractory mantle cell lymphoma RARITAN, N.J., July 10, 2013 /PRNewswire/ -- Janssen Research & Development, LLC announced the submission of a New Drug Application for ibrutinib to the U.S. Food and Drug Administration (FDA) for its use in the treatment of previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and...

2013-07-10 08:26:37

SUNNYVALE, Calif., July 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The submission was based on data from Phase II...

2013-07-08 14:15:57

A new analysis has found that among patients with chronic lymphocytic leukemia, African Americans more commonly present with advanced disease, and they tend to have shorter survival times than Caucasians despite receiving the same care. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results suggest that biological factors may account for some racial disparities in cancer survival. Among cancer patients, minorities tend to have a worse...

2013-06-20 23:34:37

Latest results of Phase 2 study confirm high rate of response, remission In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL). The most recent interim findings of the 18-center Phase 2 study were published today in the New England Journal of Medicine. Previous interim findings were presented in...

2013-06-20 23:30:02

Two clinical studies published in the New England Journal of Medicine with an accompanying editorial suggest that the novel agent ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chronic lymphocytic leukemia (CLL) and for patients with mantle cell lymphoma (MCL). Both studies, co-led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC —...

2013-06-20 16:27:14

SUNNYVALE, Calif., June 20, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced results of a study evaluating ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor in patients with Waldenstrom's Macroglobulinemia (WM). Pharmacyclics is jointly developing ibrutinib with Janssen Research & Development, LLC. The data were presented today at the International Conference on Malignant Lymphoma (ICML), taking place in Lugano,...

2013-06-20 00:21:44

SUNNYVALE, Calif., June 19, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that The New England Journal of Medicine (NEJM) published results of a Phase 2 study evaluating the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib in patients with relapsed/refractory mantle cell lymphoma (MCL) online. These data suggested ibrutinib may be effective and generally well-tolerated in patients with relapsed/refractory MCL. Results of a...

2013-06-19 20:20:48

SUNNYVALE, Calif., June 19, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that The New England Journal of Medicine (NEJM) published results online of a Phase 1b/2 study evaluating the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Ibrutinib was shown to be safe and effective in patients with relapsed/refractory CLL or...